A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naive Advanced EGFR Mutant Lung Cancer

Study Overview

This research study is studying a combination of two targeted therapies as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.

The drugs involved in this study are:

  • Osimertinib (Tagrisso)
  • Selumetinib

Study Description

A Phase 2 Study of osimertinib in combination with selumetinib in EGFR inhibitor naive advanced EGFR mutant lung cancer

  • ClinicalTrials.gov Identifier: NCT03392246
  • Protocol Number: 17-540
  • Principal Investigator: Daniel Costa

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000